PHAT Share Price Performance
US$0
-10.28 (-100.00%)
Price US$0
Fair ValueUS$23.70
Share Pricen/a
Phathom Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
PHAT Community Narratives
AN
Fair Value
·Fair Value US$23.7 64.1% undervalued intrinsic discount
PHAT: Rising Profit Margins Will Drive Stronger Shareholder Value Ahead
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value US$13.62 37.5% undervalued intrinsic discount
Rising Pricing Pressure And Regulatory Hurdles Will Impair GI Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$29 70.7% undervalued intrinsic discount
Aging Demographics And Emerging Markets Will Boost GI Adoption
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising Pricing Pressure And Regulatory Hurdles Will Impair GI Prospects
Phathom’s stomach and gut drug business faces a squeeze as healthcare payers push harder on prices and regulators raise the bar for new approvals, which could slow growth and keep costs high. At the same time, longer protection from copycat competition and strong early demand for its lead product could give it more time to broaden its lineup and work toward steady profits.Read more
AN
US$13.62
37.5% undervalued intrinsic discount
Fair Value
Profit Margin
21.06%
Future PE
11.17x
Price in 2029
US$14.32
PHAT: Rising Profit Margins Will Drive Stronger Shareholder Value Ahead
Phathom is betting big on its stomach and gut medicine VOQUEZNA, aiming to win more doctors’ prescriptions while cutting costs and extending how long it can sell the drug without copycats. The upside comes with big strings attached: the business depends heavily on one product in a tough U.S. pricing and insurance environment, and any stumble on coverage, safety, or new uses could slow the story fast.Read more
AN
US$23.7
64.1% undervalued intrinsic discount
Fair Value
Profit Margin
33.45%
Future PE
10.66x
Price in 2029
US$24.93
Aging Demographics And Emerging Markets Will Boost GI Adoption
Key Takeaways Expanding adoption among gastroenterologists, longer exclusivity for key drugs, and global demographic trends could drive sustained, above-expected revenue and profit growth. Strategic international partnerships and strong cost discipline position the company for early profitability and significant operating leverage.Read more
AN
US$29
70.7% undervalued intrinsic discount
Fair Value
Profit Margin
28.97%
Future PE
12.86x
Price in 2028
US$34.31
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
PHAT: Research Momentum And 2026 Profitability Outlook Will Support Bullish Repricing
Fair Value: US$13.62 37.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PHAT: Clinical Momentum Will Support Anticipated 2026 Profitability Timeline
Fair Value: US$23.7 64.1% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Demographics And Emerging Markets Will Boost GI Adoption
Fair Value: US$29 70.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Phathom Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -1.25
- 82.92%
- -41.34%
- -159.6%
About PHAT
- Founded
- 2018
- Employees
- 371
- CEO
- WebsiteView website
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
